Semi-Annual Consolidated Statement Of Cash Flows

ASKA Pharmaceutical Holdings CO., Ltd. - Filing #7601173

Concept 2021-04-01 to
2022-03-31
As at
2022-03-31
As at
2021-03-31
Semi-annual consolidated statement of cash flows
Statement of cash flows
Cash flows from operating activities
Subtotal
4,863,000,000 JPY
Interest and dividends received
292,000,000 JPY
Interest paid
-58,000,000 JPY
Income taxes paid
-1,385,000,000 JPY
Net cash provided by (used in) operating activities
2,842,000,000 JPY
Cash flows from investing activities
Purchase of property, plant and equipment
-579,000,000 JPY
Proceeds from sale of property, plant and equipment
10,312,000,000 JPY
Purchase of investment securities
-56,000,000 JPY
Proceeds from sale of investment securities
11,000,000 JPY
Other, net
-1,091,000,000 JPY
Net cash provided by (used in) investing activities
6,743,000,000 JPY
Cash flows from financing activities
Repayments of long-term borrowings
-2,298,000,000 JPY
Dividends paid
-398,000,000 JPY
Net cash provided by (used in) financing activities
-2,996,000,000 JPY
Effect of exchange rate change on cash and cash equivalents
0 JPY
Net increase (decrease) in cash and cash equivalents
6,589,000,000 JPY
Cash and cash equivalents
17,103,000,000 JPY
10,514,000,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.